Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | March 26, 2019 | March 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date March 26, 2019 · Filed March 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 161,540 |
Ending reported balance
After 2019-03-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-26 · Exercise / conversion · Acquired 6,000 · Balance 137,540 Row 2 · 2019-03-26 · Exercise / conversion · Acquired 12,000 · Balance 149,540 Row 3 · 2019-03-26 · Exercise / conversion · Acquired 12,000 · Balance 161,540 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.34 · Expires 2025-06-03 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-26 · Exercise / conversion · Disposed 6,000 · Balance 0 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-26 · Exercise / conversion · Disposed 12,000 · Balance 0 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.05 · Expires 2026-06-08 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-26 · Exercise / conversion · Disposed 12,000 · Balance 0 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.60 | $21,600.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-17-039002 · doc4.xml · derivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.